ADIAL PHARMACEUTICALS, INC.
ADIL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ADIL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADIL
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04, a therapeutic agent for alcohol use disorder (AUD) in genetically defined subgroups, with a pipeline also including AT177 for addiction disorders.
Key risk: Limited cash runway
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for ADIAL PHARMACEUTICALS, INC..
Similar companies
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04, a therapeutic agent for alcohol use disorder (AUD) in genetically defined subgroups, with a pipeline also including AT177 for addiction disorders.
- Adial Pharmaceuticals is focused on developing therapeutics for addiction and related disorders, with lead candidate AD04 for alcohol use disorder (AUD) [sec_mda · as of 2026-05-08].
- AD04 was investigated in a Phase 3 ONWARD trial for AUD in subjects with certain target genotypes identified via a companion diagnostic genetic test [sec_mda · as of 2026-05-08].
- The company is planning to conduct one Phase 3 trial with adaptive design, one confirmatory Phase 3 trial, and one open-label extension study for AD04 [sec_mda · as of 2026-05-08].
- As of June 30, 2026, the company reported cash and equivalents of $28.7 million, net income of -$52.0 million, and shareholders' equity of -$38.4 million [sec].
- Cash on hand is sufficient to fund operations into the second half of 2026, but additional financing will be required to continue the overall business strategy [sec_mda · as of 2026-05-08].
What works
- AD04 targets a genetically defined AUD subgroup, potentially enabling a precision medicine approach with a companion diagnostic [sec_mda · as of 2026-05-08].
- The company has raised significant capital through equity financings, including approximately $24.3 million from a PIPE in mid-2026 [sec_mda · as of 2026-08-14].
- Adial is advancing a second pipeline candidate, AT177, with an IND planned for the second quarter of 2027 [sec_mda · as of 2026-08-14].
What to weigh
- The company has incurred recurring losses and needs to raise additional funds to sustain operations [sec_mda · as of 2026-05-08].
- Cash runway is limited, with sufficient funds only into the second half of 2026 based on current commitments [sec_mda · as of 2026-05-08].
- Shareholders' equity is negative at -$38.4 million as of June 30, 2026, indicating accumulated deficits [sec].
- The clinical development program for AD04 requires multiple trials (adaptive Phase 3, confirmatory Phase 3, open-label study) before potential regulatory submission, which is capital-intensive and uncertain [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Adial is a biopharmaceutical company focused on addiction therapeutics.
“opharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders.”
SEC MD&A · May 8, 2026
AD04 is being developed for AUD in genetic subgroups with a companion diagnostic.
“AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test.”
SEC MD&A · May 8, 2026
Cash on hand is sufficient into the second half of 2026.
“Our cash on hand is sufficient to fund our operations and meet our existing commitments into the second half of 2026, based on our current commitments.”
SEC MD&A · May 8, 2026
The company raised $24.3 million from a PIPE in mid-2026.
“sold Initial Closing Pre-Funded Warrants to purchase an aggregate of 9,749,345 shares of common stock to the PIPE Investors, for net proceeds of approximately $24.3 million”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash sufficient only into H2 2026; additional financing needed soon [sec_mda · as of 2026-05-08].
- Negative shareholders' equity — Shareholders' equity of -$38.4M as of June 30, 2026 indicates accumulated losses [sec].
- Clinical and regulatory uncertainty — AD04 requires multiple Phase 3 trials and regulatory discussions; outcomes are uncertain [sec_mda · as of 2026-05-08].
- Dependence on future financing — Company has recurring losses and must raise capital to continue operations and trials [sec_mda · as of 2026-05-08].
What to watch
- Completion of the planned adaptive Phase 3 trial for AD04 and subsequent confirmatory trial [sec_mda · as of 2026-05-08].
- Regulatory feedback from FDA and EMA on the clinical development program for AD04 [sec_mda · as of 2026-05-08].
- Progress of AT177 toward an IND filing planned for Q2 2027 [sec_mda · as of 2026-08-14].
- Ability to secure additional equity or debt financing to extend cash runway beyond H2 2026 [sec_mda · as of 2026-05-08].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ADIAL PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ADIAL PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
13.6 months
OCF -$6M · Net income -$52M
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
6 buys · 0 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$61K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 24,249 | $43K |
| vanguard fiduciary trust co | 5,879 | $11K |
| manchester capital management llc | 1,923 | $3K |
| blackrock, inc. | 1,110 | $2K |
| vanguard capital management llc | 722 | $1K |
| morgan stanley | 50 | $90 |
| wells fargo & company/mn | 6 | $11 |
| northwestern mutual wealth management co | 4 | $7 |
| harbour investments, inc. | 3 | $5 |
| abound wealth management | 1 | $2 |
Short Interest
as of Apr 21, 2026- % of float
- 6.8%
- Days to cover
- 0.6
- Shares short
- 96,887
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADIL short interestFrequently asked questions
What is the AI investment thesis for ADIAL PHARMACEUTICALS, INC.?
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04, a therapeutic agent for alcohol use disorder (AUD) in genetically defined subgroups, with a pipeline also including AT177 for addiction disorders.
What is ADIAL PHARMACEUTICALS, INC.'s lead drug candidate?
ADIAL PHARMACEUTICALS, INC.'s most advanced tracked candidate is AD04 (Phase 3) for Alcohol use disorder (AUD).
Who is the CEO of ADIAL PHARMACEUTICALS, INC.?
Mr. Cary John Claiborne MBA is the chief executive officer of ADIAL PHARMACEUTICALS, INC. (ADIL).
Where is ADIAL PHARMACEUTICALS, INC. headquartered?
ADIAL PHARMACEUTICALS, INC. (ADIL) is headquartered in Glen Allen, VA, United States.
What therapeutic areas does ADIAL PHARMACEUTICALS, INC. focus on?
ADIAL PHARMACEUTICALS, INC. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.